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Abstract
Melanomas are malignant lesions stemming from the disorganized 
proliferation of melanocytes. This condition is more common on 
skin, but may also be detected in mucosa, such as in the oral cavity. 
The aim of the present study was to report similarities and differ-
ences between oral and cutaneous melanoma.
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Introduction
Melanoma originates from the malignant transformation of 
melanocytes [1]. Oral melanoma is not as common as cuta-
neous melanoma and has the worst prognosis among malig-
nant tumors [2, 3]. Due to the greater tendency toward me-
tastasis, oral melanoma is considered quite aggressive [4, 5]. 
Early diagnosis is therefore important [6]. Fortunately, both 
the oral cavity and skin is of easy access to exams, which 
may increase the chances of survival [7]. Early diagnosis and 
treatment are essential for a better prognosis regarding mela-
nomas and reduced risk of mortality [8-10].
As oral melanoma may be asymptomatic in the early 
stages,  it  is  often  only  perceived  after  the  appearance  of 
symptoms such as pain, bleeding and ulceration [9]. Most 
cases of oral melanoma (66.6%) were diagnosed in advanced 
stages, with lesions greater than 4 cm in diameter; distant 
metastases were encountered, especially in the lungs; and 
mean survival was 16.9 months, with only 6.6% of patients 
surviving more than five years [11].
The aim of the present study was to report the similari-
ties and differences between oral and cutaneous melanoma.
 
Review and Discussion
According to Rivers [12] (1996), a single melanoma occurs 
only occasionally. However, two lesions, with one as a satel-
lite to the main lesion, are relatively common [9]. This oc-
curs due to embolic propagation to the lymph vessels, with 
the development of secondary tumors a short distance from 
the primary tumor [13].
Oral melanomas are more commonly found in the max-
illa, especially in the palate and gums [1, 4-6, 14-16]. The 
mandible is only involved in 20% of cases [5, 17]. The pref-
erential location of melanoma in the head and neck is the 
nasal cavity, which may explain why oral melanoma is more 
common in the palate, considering the proximity and em-
bryological origin. As these two structures are continually 
exposed to inhaled air, it is possible that irritants and car-
cinogenic compounds in the air, such as the components of 
cigarette smoke, play a contributing role in the development 
of lesions in these sites [2]. However, the relative role of 
toxic substances, medications and hormones, such as during 
pregnancy and the use of hormonal contraceptives, remains 
unclear. Immune status also plays a determinant role in the 
course of melanoma, considering its rapid progression in im-
munosuppressed individuals [18].
Unlike cutaneous melanoma, the pathogenesis and etio-
genesis of mucosal melanoma are not yet clear or defined 
[1, 8, 15, 17, 19]. Sun exposure is not related to the etiology 
of oral melanoma, but is clearly linked to cutaneous mela-
noma. Factors such as family history, syndromes, cytogenet-
ic defects, growth factors, pre-existing lesions, mechanical 
trauma, denture use, infection, oral habits, self-medication, 
eating disorders, smoking habits and exposure to formalde-
hyde and other carcinogenic substances may have some etio-
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logical significance [5, 20]. Racial, cultural and geographic 
factors may also predispose individuals to the disease [20]. 
Japanese, African, American and Hispanic individuals are 
more commonly affected by oral melanoma, with a greater 
predilection for the male gender [1, 5, 21, 22]. However, 
Pour et al [6] (2009) reported a greater prevalence of oral 
melanoma among women. 
The genetic theory regarding the cause of the malignant 
transformation of pigmented benign tumors is founded on 
the expression of certain antigens during the transformation 
process of the benign melanocytic nevus to melanoma, with 
an alteration in the p53 protein identified in two-thirds of 
cases. Cytogenetic analysis of a specific gene in melanocytes 
seems to be very useful to the understanding of the patho-
genesis [19]. According to Tanaka et al [23] (2001), the bio-
logical behavior of melanoma may be associated to the ex-
pression of the proteins Rb, pRb2/p130, p53 and p16, which 
may be useful in predicting the appearance of this neoplasm. 
Melanoma may present as either a flat or nodular, pain-
less, dark brown or black lesion with erythema, ulceration 
and bleeding [8, 21]. The invasion of the conjunctive tissue 
with  atypical  melanocytes  alters  the  configuration  of  the 
surface of the lesion. Initially, macular melanoma develops 
in situ and may later become nodular [24]. Gorsky et al [2] 
(1998) found that oral lesions were more often diagnosed as 
nodules, with only 40% of patients complaining of pain or 
discomfort. In the clinical aspect, the majority of such lesions 
are described as non-pigmented. Bone erosion is common as 
the disease progresses [4, 21]. Deep extension, with or with-
out bone invasion, is present in the diagnosis of many cases. 
However, surface dissemination prior to vertical dissemina-
tion is possible and one third of patients with oral melanoma 
exhibit previous benign melanin pigmentation [25].
An important issue in the management of oral melanoma 
is to exclude the possibility of its being a metastasis of a cu-
taneous melanoma, which would affect the determination of 
the treatment [21]. Greene et al [26] (1953) proposed three 
useful criteria in the diagnosis of primary oral melanoma: 
the presence of malignant melanoma in the oral mucosa; the 
exclusion of melanoma in any other primary site; and the 
histopathological determination of junction activity, which 
is described as melanocytes arranged throughout the basal 
layer of the surface epithelium.
The Clark and Breslow classifications are the most of-
ten used assessment systems for the prognosis of cutaneous 
melanoma [27, 28]. While the Clark classification assesses 
the depth of the invasion, the Breslow measurement system 
analyzes the thickness of the tumor of greatest depth to the 
beginning of the granular layer. These two classification sys-
tems have not been validated as prognostic predictors of oral 
melanoma, likely due to the rarity of this lesion. Moreover, 
unlike cutaneous melanoma, more oral melanomas are larger 
than 4 mm upon initial presentation [6].
Prasad et al [29] (2004) established a three-level micro-
stage system: Level I - in situ melanoma either with no evi-
dence of invasion or with the presence of individual or ag-
glomerated invasive melanocytes with less than 10 atypical 
melanocytes near the subethelial junction; Level II - mela-
noma cells limited to the lamina propria; and Level III - inva-
sion of the deep conjunctive tissue, including skeletal mus-
cle, bone or cartilage. Barker et al [30] (1997) presented a 
variation of the histological classification: in situ melanoma, 
restricted to the epithelium; invasive melanoma, extending 
to the connective tissue; and mixed melanoma, which is a 
combination of the in situ and invasive forms.
A number of factors may contribute toward a poor prog-
nosis for oral melanoma, including the absence of symptoms 
in the early stage of the disease and difficulty determining 
the width of the radial excision due to anatomic limitations 
and rich blood supply to the region, which may facilitate 
hematogenic propagation [4, 7, 15, 19, 21, 22, 25]. Lymph 
nodes, lungs, liver and brain are common sites of metastasis 
and are often involved in advanced stages of the disease [7, 
8].
The five-year survival rate for oral melanoma is gener-
ally only between 10% and 25% due to the late detection 
stemming from the fact that this lesion is less visible than 
cutaneous melanoma [10]. Lymphatic metastasis at the time 
of diagnosis seems to be the most important prognostic fac-
tor for oral melanoma [8]. Early diagnosis and treatment can 
reduce the chances of mortality. If diagnosed early enough, 
when the malignant cells are limited to the epidermis or 
when there is minimal invasion, melanoma is 100% curable 
through surgery or is associated to a 95% five-year survival 
rate for lesions under 1 mm in thickness without ulceration. 
In contrast, the five-year survival rate for cutaneous melano-
ma with lesions larger than 4 mm in thickness and ulceration 
is only 45% [31].
Unlike with cutaneous melanoma, excision biopsy is not 
feasible for oral melanoma due to the presence of teeth and 
bone in the region [15]. Aggressive resection with the com-
plete removal of the tumor is also hindered for this reason 
and incomplete resection contributes toward recurrence or 
metastasis [4].
As with the cutaneous form, oral melanoma can usually 
be  diagnosed  with  hematoxylin-eosin  staining,  which  al-
lows easy identification of the disease through its junction 
activity, diffuse arrangement of spherical or spiny cells with 
abundant eosinophilic cytoplasm marked by cellular atypia, 
eosinophilic  nucleolus  and  abundant  mitotic  figures  [32]. 
However, if the lesion is completely devoid of pigment and 
the clinical hypothesis of melanoma is not posed, immuno-
histochemical  analysis  using  the  protein  markers  S-100, 
gp-100, HMB-45 and mart-1 is useful [10, 32]. Amelonotic 
melanoma is rare and has a worse prognosis in comparison 
to pigmented lesions due to the delayed establishment of the 
correct diagnosis and onset of treatment [6, 7].
Surgery is the most indicated form of treatment for mel-
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anoma. Depending on the stage, chemotherapy and radio-
therapy may be used as adjuvant treatment. However, when 
there  is  metastasis,  melanoma  is  incurable  in  most  cases 
[9, 11, 13]. Radiotherapy may be used as a complementary 
treatment following surgery or when previous treatment has 
failed [2]. Radiotherapy may also be used as the only treat-
ment in elderly patients or in the preoperative phase for the 
reduction of the tumor and alleviation of pain symptoms 
in cases of bone metastasis [13]. Umeda and Shimada [33] 
(1994) adopted a protocol that consists of surgery of the le-
sion through oral access, with a 1.5 cm margin of safety, ex-
cision of any lymph node with regional metastasis and the 
administration of chemotherapy. According to Smith et al 
[13] (1993), a 1cm margin is likely adequate for tumors of 
the oral cavity and a combination of treatments may provide 
greater benefits to the patient. 
Experimental studies carried out on mice and in vitro 
have demonstrated that hollow nanoparticles made of gold 
aggregated to peptides have an affinity for the receptors of 
melanoma cells and penetrate these cells. Following injec-
tion into the organism and an infrared light bath, the can-
cer cells with nanoparticles in their interior are destroyed by 
photothermal damage, with the loss of the cell membrane 
and protein denaturation. This treatment is known as plas-
monic photothermal therapy [34]. Gene therapy with the use 
of modified melanoma cells containing specific genes that 
code for cytokines, interferon and growth factors may be ad-
ministered, such as tumor cell vaccines [12]. Immunotherapy 
may also be incorporated to melanoma treatment, although 
patient immune response may be significantly altered by the 
clinical course of the neoplasm [35]. Interleukin-2, interfer-
on alpha, tumor-infiltrating lymphocytes, bacillus Calmette-
Guerin,  irradiated  allogeneic  tumor  cells  and  monoclonal 
antibodies can be used [36].
Preoperative investigations, such as chest x-ray, kidney 
function test and abdominal ultrasound, should be performed 
for the identification of metastasis. In the determination of 
bone metastasis, computed tomography reveals the extent of 
invasion into structures adjacent to the mouth, such as the 
nasal cavity or eye, and a possible recurrence of metastasis 
in regional lymph nodes. When there is distant metastasis 
due to hematogenic propagation, aggressive surgery is not 
indicated and either only local palliative excision or no sur-
gery is recommended. Regional metastasis is uncommon, 
but, when it occurs, there is local recurrence and distant me-
tastasis in the majority of cases [13]. For melanomas greater 
than 1 mm in thickness, ultrasonography of the lymph nodes 
and abdomen (including the pelvis and retroperitoneum) are 
indicated. The first five years following surgery are the most 
important, with 90% of all cases of metastasis occurring in 
this period [18].
Health  care  professionals  should  be  attentive  to  pig-
mented lesions in the mucosa as well as skin, carrying out 
detailed, discerning exams. Mucosal melanoma, especially 
in the oral cavity, is rare, but is more aggressive and has a 
poorer prognosis. Nonetheless, if diagnosed early, complete 
cure is possible. 
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